The current treatment of recurrent ovarian cancer

被引：51

作者：

Herzog T.J. ^{[1
]}

机构：

[1] Division of Gynecologic Oncology, Department of Obstetrics anf Gynecology, Columbia University, New York, NY 10032

来源：

Current Oncology Reports | 2006年 / 8卷 / 6期

关键词：

Ovarian Cancer; Bevacizumab; Gemcitabine; Topotecan; Liposomal Doxorubicin;

D O I：

10.1007/s11912-006-0074-9

中图分类号：

学科分类号：

摘要：

Contemporary management of recurrent ovarian, primary peritoneal, and fallopian tube cancers has continued to evolve and now offers women the hope of extended survival with an improved quality of life. Platinum continues to be the single most active agent in the treatment of ovarian cancer, but acquired resistance to platinum often emerges. Fortunately, a number of novel agents and treatment strategies have been developed to meet the goal of ameliorating symptoms while extending survival. Classically, patients have been treated based upon the interval from last platinum administration during front-line therapy until time of recurrence. This review focuses upon the current treatment strategies used for platinum-refractory, platinum-resistant, and platinum-sensitive patients. The incorporation of targeted biologic agents is also discussed, along with the role of secondary cytoreduction. It is hoped that the results of future and ongoing clinical trials will offer further advances in the treatment of this devastating disease. Copyright © 2006 by Current Science Inc.

引用

页码：448 / 454

页数：6

共 48 条

[1]

Jemal A., Siegel R., Ward E., Et al., Cancer statistics, 2006, CA Cancer J Clin, 56, pp. 106-130, (2006)

[2]

Bristow R.E., Tomacruz R.S., Armstrong D.K., Et al., Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis, J Clin Oncol, 20, pp. 248-259, (2002)

[3]

Armstrong D.K., Bundy B., Wenzel L., Et al., Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N Engl J Med, 354, pp. 34-43, (2006)

[4]

Markman M., Liu P.Y., Wilczynski S., Et al., Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial, J Clin Oncol, 21, pp. 2460-2465, (2003)

[5]

Markman M., Rothman R., Hakes T., Et al., Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, J Clin Oncol, 9, pp. 389-393, (1991)

[6]

Herzog T.J., Recurrent ovarian cancer: How important is it to treat to disease progression?, Clin Cancer Res, 10, pp. 7439-7449, (2004)

[7]

Sehouli J., Oskay-Ozcelik G., Kuhne J., Et al., Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: Results of a multicenter phase-II trial, Ann Oncol, 17, pp. 957-961, (2006)

[8]

Rose P.G., Pegylated liposomal doxorubicin: Optimizing the dosing schedule in ovarian cancer, Oncologist, 10, pp. 205-214, (2005)

[9]

Markman M., Gordon A.N., McGuire W.P., Muggia F.M., Liposomal anthracycline treatment for ovarian cancer, Semin Oncol, 31, SUPPL. 13, pp. 91-105, (2005)

[10]

Gordon N., Fleagle J.T., Guthrie D., Et al., Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J Clin Oncol, 19, pp. 3312-3322, (2001)

← 1 2 3 4 5 →